




Searching News Database: glioblastoma
HSMN NewsFeed - 31 Dec 2024
Kazia Therapeutics Provides Update on Paxalisib Regulatory Pathway Following Type C Meeting with FDA
Kazia Therapeutics Provides Update on Paxalisib Regulatory Pathway Following Type C Meeting with FDA
HSMN NewsFeed - 30 May 2024
US FDA Awards Supplemental Orphan Drug Designation to Survaxm to Now Include Treatment of Malignant Glioma
US FDA Awards Supplemental Orphan Drug Designation to Survaxm to Now Include Treatment of Malignant Glioma
HSMN NewsFeed - 18 Dec 2023
NeuExcell's AAV Gene Therapy for Malignant Glioma Granted Orphan Drug Designation by FDA
NeuExcell's AAV Gene Therapy for Malignant Glioma Granted Orphan Drug Designation by FDA
HSMN NewsFeed - 17 Nov 2021
Alpheus Medical Closes $16M In Series A Financing For Novel Glioma Brain Cancer Treatment
Alpheus Medical Closes $16M In Series A Financing For Novel Glioma Brain Cancer Treatment
HSMN NewsFeed - 8 Oct 2021
Alpha Tau Receives FDA's Breakthrough Device Designation for the Treatment of Recurrent GBM
Alpha Tau Receives FDA's Breakthrough Device Designation for the Treatment of Recurrent GBM
HSMN NewsFeed - 17 May 2021
INOVIO Announces Appointment Of Roger Dansey, M.D., to its Board of Directors
INOVIO Announces Appointment Of Roger Dansey, M.D., to its Board of Directors
HSMN NewsFeed - 11 Jan 2021
Valo Raises $190 Million in Series B Financing and Unveils Select Therapeutic Programs
Valo Raises $190 Million in Series B Financing and Unveils Select Therapeutic Programs
HSMN NewsFeed - 6 Jan 2021
Myeloid Therapeutics Launches with Over $50 Million in Financing and Two Clinical Trials
Myeloid Therapeutics Launches with Over $50 Million in Financing and Two Clinical Trials
HSMN NewsFeed - 23 Jul 2020
Quadriga BioSciences Initiates Clinical Trial of Innovative, Targeted Treatment for Brain Cancers
Quadriga BioSciences Initiates Clinical Trial of Innovative, Targeted Treatment for Brain Cancers
HSMN NewsFeed - 11 Jun 2020
CNS Announces the FDA has Granted Orphan Drug Designation for Brain Cancer Drug Berubicin
CNS Announces the FDA has Granted Orphan Drug Designation for Brain Cancer Drug Berubicin
HSMN NewsFeed - 13 Jan 2020
CNS Pharmaceuticals Licenses DNA-Binding Agent from MD Anderson, Doubling its Drug Pipeline
CNS Pharmaceuticals Licenses DNA-Binding Agent from MD Anderson, Doubling its Drug Pipeline
HSMN NewsFeed - 6 Jan 2020
CARsgen Appoints Yong Fan as Senior Vice President of Global Regulatory Affairs
CARsgen Appoints Yong Fan as Senior Vice President of Global Regulatory Affairs
HSMN NewsFeed - 26 Nov 2019
CNS Pharmaceuticals Entered $2.0 Million Sublicense Agreement with WPD Pharmaceuticals
CNS Pharmaceuticals Entered $2.0 Million Sublicense Agreement with WPD Pharmaceuticals
HSMN NewsFeed - 19 Nov 2019
CNS Pharmaceuticals Acquired Worldwide Rights for Brain Cancer Drug from Houston Pharmaceuticals
CNS Pharmaceuticals Acquired Worldwide Rights for Brain Cancer Drug from Houston Pharmaceuticals
HSMN NewsFeed - 12 Sep 2019
Tocagen Reports Results of Toca 5 Phase 3 Trial in Recurrent Brain Cancer
Tocagen Reports Results of Toca 5 Phase 3 Trial in Recurrent Brain Cancer
HSMN NewsFeed - 19 Jun 2019
CARsgen Therapeutics Receives IND Clearance for BCMA-CAR-T Cells from the U.S. FDA
CARsgen Therapeutics Receives IND Clearance for BCMA-CAR-T Cells from the U.S. FDA
HSMN NewsFeed - 24 Sep 2018
Tocagen Appoints Mohamed Ladha as Vice President to Establish Commercial Organization
Tocagen Appoints Mohamed Ladha as Vice President to Establish Commercial Organization
HSMN NewsFeed - 5 Dec 2017
OncoSec Announces Promotion of Christopher G. Twitty, Ph.D. to Chief Scientific Officer
OncoSec Announces Promotion of Christopher G. Twitty, Ph.D. to Chief Scientific Officer
HSMN NewsFeed - 3 Oct 2017
Oncorus(R), Inc., Names Christophe Quéva, Ph.D., as Chief Scientific Officer
Oncorus(R), Inc., Names Christophe Quéva, Ph.D., as Chief Scientific Officer
HSMN NewsFeed - 8 May 2017
Regeneron and Inovio Enter Immuno-Oncology Clinical Study Agreement for Glioblastoma Combination Therapy
Regeneron and Inovio Enter Immuno-Oncology Clinical Study Agreement for Glioblastoma Combination Therapy
HSMN NewsFeed - 28 Apr 2017
Sorrento Therapeutics Announces Closing of its Acquisition of Virttu Biologics
Sorrento Therapeutics Announces Closing of its Acquisition of Virttu Biologics
HSMN NewsFeed - 24 Apr 2017
Mustang Bio Announces Appointment of Manuel Litchman, M.D., as President and Chief Executive Officer
Mustang Bio Announces Appointment of Manuel Litchman, M.D., as President and Chief Executive Officer
HSMN NewsFeed - 31 Oct 2016
Novogen Acquires Privately-held Neuro-oncology Company to Support Development of GDC-0084 in Glioblastoma
Novogen Acquires Privately-held Neuro-oncology Company to Support Development of GDC-0084 in Glioblastoma
HSMN NewsFeed - 8 Aug 2016
Inspyr Therapeutics Appoints Ronald Shazer, M.D., as Senior Vice President and Chief Medical Officer
Inspyr Therapeutics Appoints Ronald Shazer, M.D., as Senior Vice President and Chief Medical Officer
HSMN NewsFeed - 4 Aug 2016
Inspyr Therapeutics Appoints Christopher Lowe Chief Executive Officer and Director
Inspyr Therapeutics Appoints Christopher Lowe Chief Executive Officer and Director
HSMN NewsFeed - 26 Jul 2016
NCCN Guidelines Recommend Optune as a Standard Treatment Option for Newly Diagnosed Glioblastoma
NCCN Guidelines Recommend Optune as a Standard Treatment Option for Newly Diagnosed Glioblastoma
HSMN NewsFeed - 19 Nov 2015
Triphase Accelerator Corporation Announces FDA Orphan Drug Designation for Marizomib in Malignant Glioma
Triphase Accelerator Corporation Announces FDA Orphan Drug Designation for Marizomib in Malignant Glioma
HSMN NewsFeed - 5 Oct 2015
Novocure Announces CE Mark and First Patient Use of Second Generation Optune System
Novocure Announces CE Mark and First Patient Use of Second Generation Optune System
HSMN NewsFeed - 22 Sep 2015
ImmunoCellular Therapeutics Appoints Mark A. Schlossberg and Gregg A. Lapointe to its Board of Directors
ImmunoCellular Therapeutics Appoints Mark A. Schlossberg and Gregg A. Lapointe to its Board of Directors
HSMN NewsFeed - 6 Jan 2015
CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results in Glioblastoma Multiforme (Brain Cancer)
CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results in Glioblastoma Multiforme (Brain Cancer)
HSMN NewsFeed - 18 Sep 2014
NOXXON Pharma Expands Management Team by Appointing Don Munoz as Chief Financial Officer
NOXXON Pharma Expands Management Team by Appointing Don Munoz as Chief Financial Officer
HSMN NewsFeed - 16 Jan 2014
CytRx Appoints Shanta Chawla, M.D. as Vice President, Clinical Development
CytRx Appoints Shanta Chawla, M.D. as Vice President, Clinical Development
HSMN NewsFeed - 12 Aug 2013
Teva Pharmaceutical And Perrigo Company Announce The U.S. Launch Of Generic Temozolomide
Teva Pharmaceutical And Perrigo Company Announce The U.S. Launch Of Generic Temozolomide
HSMN NewsFeed - 22 Jan 2013
NCCN Guidelines(R) Recommend NovoTTF(TM) Therapy as a Standard Treatment Option for CNS Cancers
NCCN Guidelines(R) Recommend NovoTTF(TM) Therapy as a Standard Treatment Option for CNS Cancers
HSMN NewsFeed - 3 Dec 2012
ImmunoCellular Therapeutics Appoints Andrew Gengos as Chief Executive Officer
ImmunoCellular Therapeutics Appoints Andrew Gengos as Chief Executive Officer
HSMN NewsFeed - 2 Oct 2012
Cell Therapeutics OPAXIOTM Receives Orphan Drug Designation for Malignant Brain Cancer from FDA
Cell Therapeutics OPAXIOTM Receives Orphan Drug Designation for Malignant Brain Cancer from FDA
HSMN NewsFeed - 28 Mar 2012
Kapil Dhingra, Former Head of Roche Oncology, Joins Exosome Diagnostics Board of Directors
Kapil Dhingra, Former Head of Roche Oncology, Joins Exosome Diagnostics Board of Directors
HSMN NewsFeed - 26 Mar 2012
MagForce AG Announces Company Restructuring and Revised Corporate Strategy for 2012
MagForce AG Announces Company Restructuring and Revised Corporate Strategy for 2012
HSMN NewsFeed - 13 Feb 2012
Delcath Appoints Industry Veteran Chris Houchins as Senior Vice President of Clinical and Medical Affairs
Delcath Appoints Industry Veteran Chris Houchins as Senior Vice President of Clinical and Medical Affairs
HSMN NewsFeed - 22 Nov 2011
IsoRay Receives Final Regulatory Approval for GliaSite(R) Brain Cancer Treatment
IsoRay Receives Final Regulatory Approval for GliaSite(R) Brain Cancer Treatment
HSMN NewsFeed - 10 Oct 2011
MagForce AG Announces Treatment of Recurrent Glioblastoma Patient with NanoTherm(R) Therapy
MagForce AG Announces Treatment of Recurrent Glioblastoma Patient with NanoTherm(R) Therapy
HSMN NewsFeed - 9 Jun 2011
Northwest Biotherapeutics Announces Change and Expansion of Management Team
Northwest Biotherapeutics Announces Change and Expansion of Management Team
HSMN NewsFeed - 28 Apr 2011
Arno Therapeutics Announces the Appointment of Mr. Glenn Mattes as President and Chief Executive Officer
Arno Therapeutics Announces the Appointment of Mr. Glenn Mattes as President and Chief Executive Officer
HSMN NewsFeed - 10 Jan 2011
Exelixis’ XL184 Granted Orphan Drug Designation and Assigned the Generic Name Cabozantinib
Exelixis’ XL184 Granted Orphan Drug Designation and Assigned the Generic Name Cabozantinib
HSMN NewsFeed - 14 Oct 2010
YM Biosciences Appoints Dr. Nick Glover as Chief Executive Officer and Announces Annual Meeting
YM Biosciences Appoints Dr. Nick Glover as Chief Executive Officer and Announces Annual Meeting
HSMN NewsFeed - 17 Jun 2010
Bayer and OncoMed Pharmaceuticals Enter Strategic Alliance to Develop Anti-Cancer Stem Cell Therapeutics
Bayer and OncoMed Pharmaceuticals Enter Strategic Alliance to Develop Anti-Cancer Stem Cell Therapeutics
HSMN NewsFeed - 19 Apr 2010
Myriad Pharmaceuticals Announces Termination of Merger Agreement With Javelin Pharmaceuticals
Myriad Pharmaceuticals Announces Termination of Merger Agreement With Javelin Pharmaceuticals
HSMN NewsFeed - 12 Apr 2010
Myriad Pharmaceuticals Receives Notice of Javelin's Intent to Terminate Merger Agreement
Myriad Pharmaceuticals Receives Notice of Javelin's Intent to Terminate Merger Agreement
HSMN NewsFeed - 22 Mar 2010
PhytoMedical Announces the Appointment of Dr. James F. Lynch as President and CEO
PhytoMedical Announces the Appointment of Dr. James F. Lynch as President and CEO
HSMN NewsFeed - 25 Feb 2010
Pharmaceutical Industry Veteran is Appointed CMO at Kinex Pharmaceuticals
Pharmaceutical Industry Veteran is Appointed CMO at Kinex Pharmaceuticals
HSMN NewsFeed - 1 Jul 2009
Myriad Pharmaceuticals, Inc. Established as an Independent Pharmaceutical Development Company
Myriad Pharmaceuticals, Inc. Established as an Independent Pharmaceutical Development Company
HSMN NewsFeed - 4 Jun 2009
ImmunoCellular Therapeutics Reports Additional Data from Promising Brain Cancer Clinical Trial
ImmunoCellular Therapeutics Reports Additional Data from Promising Brain Cancer Clinical Trial
HSMN NewsFeed - 1 Jun 2009
UK's NICE Recommends Use of Erbitux for Metastatic Colorectal Cancer Patients
UK's NICE Recommends Use of Erbitux for Metastatic Colorectal Cancer Patients
HSMN NewsFeed - 22 Apr 2009
Immunomedics Reports Results That Could Expand Use of Milatuzumab in Cancer Therapy
Immunomedics Reports Results That Could Expand Use of Milatuzumab in Cancer Therapy
HSMN NewsFeed - 22 Dec 2008
TransMolecular Receives Orphan Drug Designation for 131I-TM601 for the Treatment of Melanoma
TransMolecular Receives Orphan Drug Designation for 131I-TM601 for the Treatment of Melanoma
HSMN NewsFeed - 22 Dec 2008
Myriad Genetics Launches Sixth Personalized Medicine Product, Prezeon -- to Reveal PTEN Status
Myriad Genetics Launches Sixth Personalized Medicine Product, Prezeon -- to Reveal PTEN Status
HSMN NewsFeed - 12 Dec 2008
Bristol-Myers Squibb and Exelixis Enter Global Collaboration on Two Novel Cancer Programs
Bristol-Myers Squibb and Exelixis Enter Global Collaboration on Two Novel Cancer Programs
HSMN NewsFeed - 23 Jul 2008
Bradmer initiates enrollment in Phase III GLASS-ART Trial in primary glioblastoma multiforme
Bradmer initiates enrollment in Phase III GLASS-ART Trial in primary glioblastoma multiforme
HSMN NewsFeed - 31 May 2008
Amgen Presents New Data at ASCO on Four Investigational Molecules from Oncology Pipeline
Amgen Presents New Data at ASCO on Four Investigational Molecules from Oncology Pipeline
HSMN NewsFeed - 21 May 2008
AVANT Immunotherapeutics Announces Hart-Scott Rodino Clearance to License Cancer Vaccine to Pfizer
AVANT Immunotherapeutics Announces Hart-Scott Rodino Clearance to License Cancer Vaccine to Pfizer
HSMN NewsFeed - 9 Apr 2008
Novacea Receives Notification From Schering-Plough of Termination of Collaboration Agreement
Novacea Receives Notification From Schering-Plough of Termination of Collaboration Agreement
HSMN NewsFeed - 14 Mar 2008
Genentech Provides Business Update at Annual Investment Community Meeting
Genentech Provides Business Update at Annual Investment Community Meeting
HSMN NewsFeed - 11 Mar 2008
Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
HSMN NewsFeed - 21 Feb 2008
ImmunoCellular Therapeutics Announces New President and Chief Executive Officer
ImmunoCellular Therapeutics Announces New President and Chief Executive Officer
HSMN NewsFeed - 7 Feb 2008
Elekta Users First to Treat Patients with Volumetric Intensity Modulated Arc Therapy (VMAT)
Elekta Users First to Treat Patients with Volumetric Intensity Modulated Arc Therapy (VMAT)
HSMN NewsFeed - 22 Jan 2008
Exelixis and Bristol-Myers Squibb to Co-Develop XL139, an Inhibitor of the Hedgehog Pathway
Exelixis and Bristol-Myers Squibb to Co-Develop XL139, an Inhibitor of the Hedgehog Pathway
HSMN NewsFeed - 22 Oct 2007
AVANT Immunotherapeutics, Inc. and Celldex Therapeutics, Inc. Announce Merger Agreement
AVANT Immunotherapeutics, Inc. and Celldex Therapeutics, Inc. Announce Merger Agreement
HSMN NewsFeed - 2 Aug 2007
Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
HSMN NewsFeed - 9 Jul 2007
World's First Therapeutic Vaccine for Brain Cancer Commercially Available to Patients in Switzerland
World's First Therapeutic Vaccine for Brain Cancer Commercially Available to Patients in Switzerland
HSMN NewsFeed - 26 Jun 2007
Medical University of South Carolina Initiates New Trial of Cotara(R) in Brain Cancer Patients
Medical University of South Carolina Initiates New Trial of Cotara(R) in Brain Cancer Patients
HSMN NewsFeed - 25 Jun 2007
Peregrine Pharmaceuticals Initiates Patient Enrollment In New Cotara(R) Brain Cancer Trial
Peregrine Pharmaceuticals Initiates Patient Enrollment In New Cotara(R) Brain Cancer Trial
HSMN NewsFeed - 4 Jun 2007
Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
HSMN NewsFeed - 2 Jun 2007
Targeted, Oral Agent Enzastaurin Shows Favorable Results in Late-Stage Lung Cancer
Targeted, Oral Agent Enzastaurin Shows Favorable Results in Late-Stage Lung Cancer
HSMN NewsFeed - 29 May 2007
EntreMed Commences Phase 2 Clinical Trial Combining Panzem(R) NCD and Temodar(R) in Brain Cancer Patients
EntreMed Commences Phase 2 Clinical Trial Combining Panzem(R) NCD and Temodar(R) in Brain Cancer Patients
HSMN NewsFeed - 19 Apr 2007
Access Pharmaceuticals Signs Definitive Merger Agreement With Somanta Pharmaceuticals
Access Pharmaceuticals Signs Definitive Merger Agreement With Somanta Pharmaceuticals
HSMN NewsFeed - 19 Apr 2007
Novacea Acquires Worldwide Development and Commercialization Rights for Its Oncology Candidate AQ4N
Novacea Acquires Worldwide Development and Commercialization Rights for Its Oncology Candidate AQ4N
HSMN NewsFeed - 8 Mar 2007
Myriad Genetics Initiates Phase 2 Clinical Trial of Azixa(TM) in Brain Cancer
Myriad Genetics Initiates Phase 2 Clinical Trial of Azixa(TM) in Brain Cancer
HSMN NewsFeed - 21 Feb 2007
Access Pharmaceuticals Signs Letter of Intent to Acquire Somanta Pharmaceuticals
Access Pharmaceuticals Signs Letter of Intent to Acquire Somanta Pharmaceuticals
HSMN NewsFeed - 14 Feb 2007
Light Sciences Oncology Initiates Phase II Trial of Litx(TM) Therapy in Patients with Glioma
Light Sciences Oncology Initiates Phase II Trial of Litx(TM) Therapy in Patients with Glioma
HSMN NewsFeed - 16 Jan 2007
Peregrine Pharmaceuticals' Tumor Necrosis Therapy Product for the Treatment of Lung Cancer Launched in China
Peregrine Pharmaceuticals' Tumor Necrosis Therapy Product for the Treatment of Lung Cancer Launched in China
HSMN NewsFeed - 21 Dec 2006
Data Monitoring Committee Recommends Closing Enrollment in Recurrent Glioblastoma Study
Data Monitoring Committee Recommends Closing Enrollment in Recurrent Glioblastoma Study
HSMN NewsFeed - 20 Nov 2006
Gliadel(R) Wafer Clinical Data Presented at Society for Neuro-Oncology Meeting
Gliadel(R) Wafer Clinical Data Presented at Society for Neuro-Oncology Meeting
HSMN NewsFeed - 12 Oct 2006
Peregrine Receives Regulatory Approval for New Cotara(R) Brain Cancer Clinical Trial
Peregrine Receives Regulatory Approval for New Cotara(R) Brain Cancer Clinical Trial
HSMN NewsFeed - 20 Sep 2006
British Journal of Haematology Publishes Thrombosis Findings From ASCENT Trial
British Journal of Haematology Publishes Thrombosis Findings From ASCENT Trial
HSMN NewsFeed - 28 Jun 2006
EntreMed Granted Orphan Drug Designation for Panzem(R) (2ME2) In Glioblastoma
EntreMed Granted Orphan Drug Designation for Panzem(R) (2ME2) In Glioblastoma
Additional items found! 89

Members Archive contains
89 additional stories matching:
glioblastoma
(Password required)
glioblastoma
(Password required)